CSL Ltd

CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. It operates through the following segments: CSL Behring, CSL Seqirus, and CSL Vifor. The CSL Behring segment provides plasma products, gene therapies, and recombinants. The CSL Seqirus segment includes predominantly influenza related products and provides pandemic services to governments. The CSL Vidor segment focuses on the distribution of products in the therapeutic areas of iron deficiency and nephrology. The company was founded on November 2, 1961 and is headquartered in Melbourne, Australia.

Arcturus Therapeutics

KING OF PRUSSIA, Pa. , Nov. 1, 2022 /PRNewswire/ -- CSL Limited (ASX:CSL; USOTC:CSLLY) today announces that its subsidiary, CSL Seqirus, has entered into a collaboration and license agreement with Arcturus Therapeutics Holdings Inc ("Arcturus Therapeutics") to access their late stage self-amplifying mRNA (sa-mRNA) vaccine platform technology.

CSL Enters Licensing Agreement with Arcturus Therapeutics for Next Generation mRNA Vaccine Technology

ST. GALLEN, Switzerland--(BUSINESS WIRE)--Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART.

Approval of extension of exemptions from SIX disclosure and publicity obligations

ST. GALLEN, SWITZERLAND--(BUSINESS WIRE)--Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART.

Approval of delisting of Vifor Pharma AG's registered shares

New Centers in Stockton and Hayward join other CSL Plasma locations in California to help meet growing demand for medicines derived from plasma BOCA RATON, Fla. , Oct. 11, 2022 /PRNewswire/ -- CSL Plasma, the plasma collection business of global biotherapeutics leader CSL Behring, today announced the opening of additional plasma collection centers in Stockton and Hayward, California, bringing the number of CSL Plasma donation centers in the state to five.

CSL Plasma Expands in California with New Donation Centers to Collect Life-Saving Plasma

CSL Seqirus will manufacture and clinically assess a cell-based, adjuvanted pre-pandemic influenza vaccine candidate to support the U.S. government's pandemic preparedness activities Third influenza pandemic preparedness award to CSL Seqirus under a multi-year agreement with Biomedical Advanced Research and Development Authority (BARDA) SUMMIT, N.J. , Oct. 6, 2022 /PRNewswire/ -- CSL Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX: CSL), today announced that the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), selected CSL Seqirus to deliver an H5N8 A/Astrakhan virus vaccine candidate for assessment in a Phase 2 clinical study that is anticipated to begin in Q2 2023.

CSL Seqirus Announces U.S. Government Award to Manufacture and Clinically Assess Influenza A(H5N8) Pre-Pandemic Vaccine

Data published in Molecular Therapy – Methods and Clinical Development confirm the potential preclinical benefit of the sa-mRNA technology platform, the next generation of mRNA vaccine technology CAMBRIDGE, Mass. , Oct. 5, 2022 /PRNewswire/ -- Global biotech leader CSL (ASX:CSL) today announced results from the preclinical studies of the company's self-amplifying messenger RNA (sa-mRNA) influenza vaccine candidates, the next generation of mRNA vaccines.

CSL Announces Positive Preclinical Data for Self-Amplifying Messenger RNA (sa-mRNA) Influenza Vaccine Candidates

SUMMIT, N.J. , Sept. 26, 2022 /PRNewswire/ -- CSL Seqirus, a business of CSL Limited (ASX:CSL), today announced new data highlighting the significant burden influenza places on hospitals and healthcare resource use, as well as on more vulnerable populations such as children.

New Data at OPTIONS XI Conference Highlight Burden of Seasonal Influenza on Health Systems and the Need for Increased Vaccination Rates

SUMMIT, N.J. , Sept. 26, 2022 /PRNewswire/ -- CSL Seqirus, a business of CSL Limited (ASX:CSL), today announced new data from four real-world studies showing the impact that cell-based and adjuvanted influenza vaccines can have in reducing the burden of seasonal influenza on hospitals and health systems.

New Real-World Data Presented at OPTIONS XI Show Cell-Based and MF59®-Adjuvanted Influenza Vaccines Can Reduce the Burden of Seasonal Influenza on Hospitals and Health Systems

The new facility, once fully open later this calendar year, will be CSL's largest R&D site under one roof, with more than 500 team members working in a state-of-the-art facility offering access to promising scientific partners and talent. MARBURG, Germany, Sept.

CSL presents new research and development center in Marburg, Germany

SUMMIT, N.J. , Sept. 13, 2022 /PRNewswire/ -- CSL Seqirus, a part of CSL Limited (ASX:CSL), today announced new data will be presented at the Options for the Control of Influenza (OPTIONS XI) conference taking place September 26-29, 2022 in Belfast, United Kingdom.

CSL Seqirus to Highlight Commitment to Influenza Protection with More than 20 Data Presentations at OPTIONS XI

Vouchers enable donors at 300+ U.S. CSL Plasma donation centers to receive free flu shots at Walgreens pharmacy locations nationally BOCA RATON, Fla. , Sept. 8, 2022 /PRNewswire/ -- For the third year, CSL Plasma will provide influenza (flu) vaccination vouchers to U.S. plasma donors following the completion of two plasma donations made within a calendar month.

CSL Plasma Provides Free Flu Vaccines to U.S. Plasma Donors

ST. GALLEN, Switzerland--(BUSINESS WIRE)--Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced that the U.S. District Court for the District of Delaware issued a judgment in VFMCRP's favor regarding U.S. patent no. 9,561,251 which covers the formulation for Velphoro® (sucroferric oxyhydroxide). The decision, subject to appeal, holds that the generic sucroferric oxyhydroxide product proposed by Teva Pharmaceuticals USA, Inc., in its Abbreviated New Drug Application (ANDA) will infr

VFMCRP announces U.S. Court upholds validity of Velphoro® patent

ST. GALLEN, Switzerland--(BUSINESS WIRE)--Vifor Fresenius Medical Care Renal Pharma (VFMCRP) is pleased to announce that England's National Institute for Health and Care Excellence (NICE) has recommended Tavneos® in combination with a rituximab or cyclophosphamide regimen for the treatment of adult patients with severe, active granulomatosis polyangiitis (GPA) or microscopic polyangiitis (MPA), two main forms of AAV. The decision follows authorization from the UK's Medicines and Healthcare prod

Tavneos® (avacopan) recommended by England's NICE for the treatment of AAV (GPA/MPA)

CSL is on track to file for regulatory approvals at the end of the current fiscal year and will present full data set at an upcoming scientific congress KING OF PRUSSIA, Pa. , Aug. 17, 2022 /PRNewswire/ -- Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY), today announced positive top-line Phase 3 results for garadacimab (CSL312), the company's investigational first-in-class monoclonal antibody inhibiting Factor XIIa being developed as a long-term preventive treatment for patients with hereditary angioedema (HAE).

CSL Announces Positive Top-Line Phase 3 Results for Garadacimab as Preventive Treatment in Patients with Hereditary Angioedema (HAE)

CSL Limited (OTCPK:CSLLY) Q4 2022 Earnings Conference Call August 16, 2022 9:00 PM ET Company Participants Mark Dehring - Head, Investor Relations Paul Perreault - Chief Executive Officer Joy Linton - Chief Financial Officer Paul McKenzie - Chief Operating Officer Conference Call Participants Andrew Goodsall - MST Marquee Saul Hadassin - Barrenjoey David Low - JPMorgan Chris Cooper - Goldman Sachs Sean Laaman - Morgan Stanley Gretel Janu - Credit Suisse Steve Wheen - Jarden David Bailey - Macquarie David Stanton - Jefferies Craig Wong-Pan - Royal Bank of Canada John Deakin-Bell - Citi Lyanne Harrison - Bank of America Operator Thank you for standing by and welcome to the CSL Limited Full Year Financial Results Conference Call. [Operator Instructions] I'd now like to hand the conference over to Mr.

CSL Limited (CSLLY) CEO Paul Perreault on Q4 2022 Results - Earnings Call Transcript

MELBOURNE, Australia , Aug. 16, 2022 /PRNewswire/ -- CSL Limited (ASX: CSL) Today, CSL advances its vision for a more sustainable future by setting new, tangible targets for carbon emissions reductions. As part of the company's broader sustainability strategy to build a more sustainable future for employees, communities, patients and donors, CSL is announcing new carbon emissions reductions targets that will serve as a transparent roadmap to decarbonise global operations by cutting direct and indirect carbon emissions.

CSL announces carbon emissions reduction targets

All business units will incorporate CSL name and branding to signify one company MELBOURNE, Australia , Aug. 10, 2022 /PRNewswire/ -- Global biotech leader CSL today announced that all business units will be united as one family under the CSL global brand. "As a purpose-driven organization, CSL has delivered biotechnology excellence for over a century," said Paul Perreault, Chief Executive Officer and Managing Director of CSL.

CSL LAUNCHES NEW UNIFIED GLOBAL BRAND IDENTITY

New technology is designed to reduce collection time and improve donor experience; Aurora, Colorado, location is first of 300-plus CSL Plasma U.S. centers to convert to Rika Plasma Donation System BOCA RATON, Fla., Aug. 4, 2022 /PRNewswire/ -- CSL Plasma , the plasma collection business of global biotherapeutics leader CSL Behring, today began a new era in plasma donations, collecting its first plasma donations using leading-edge plasma collection technology that is expected to significantly reduce average collection time – by approximately one-third – and improve the donor experience.

CSL Plasma Reimagines Donor Experience With First Donations Completed on Innovative Plasma Collection Technology

MELBOURNE, Australia & ST. GALLEN, Switzerland--(BUSINESS WIRE)--Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR CSL Limited (ASX: CSL; USOTC:CSLLY) is pleased to announce it has now received all necessary regulatory clearances for the acquisition of Vifor Pharma AG (Vifor) announced on 14 December 2021. CSL has set the settlement date of the public tender offer for Vifor for 9 August 2022. If the offer conditions that remain in effect until the settlement remain fulfilled until tha

Finalization of Vifor Pharma acquisition

MELBOURNE, Australia & ST. GALLEN, Switzerland--(BUSINESS WIRE)--Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR CSL Limited (ASX: CSL; USOTC:CSLLY) today announced an update regarding the Vifor Pharma AG acquisition. On January 18, 2022, CSL Behring AG (the Offeror) published the offer prospectus (the Offer Prospectus) for its public tender offer according to articles 125 et seq. FMIA (the Offer) for all publicly held registered shares of Vifor Pharma Ltd. (Vifor) with a nominal va

Extension of the postponement of the settlement of Vifor Pharma tender offer

This year marks the first full season that Seqirus' portfolio of innovative influenza vaccines provides a differentiated vaccine option for people of all ages who are eligible in the U.S. to receive a flu shot Seqirus will offer FLUCELVAX® QUADRIVALENT (Influenza Vaccine), the first and only cell-based quadrivalent influenza vaccine, which is now available for eligible persons six months of age and older 1 Seqirus will offer FLUAD® QUADRIVALENT (Influenza Vaccine, Adjuvanted), which is now preferentially recommended by the CDC's Advisory Committee for Immunization Practices as one of the preferred vaccine options for adults 65 years and older, over standard dose influenza vaccines2 SUMMIT, N.J. , July 11, 2022 /PRNewswire/ -- Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX:CSL), today announced that it has begun to ship its portfolio of innovative cell-based, adjuvanted and egg-based seasonal influenza vaccines across the U.S. in preparation for the 2022/23 influenza season.

Seqirus Begins Shipping Portfolio of Innovative Influenza Vaccines for the 2022/23 U.S. Season

ACIP recommends adults 65 years of age and older receive an enhanced flu vaccine, such as FLUAD ® QUADRIVALENT (Influenza Vaccine, Adjuvanted), to help protect against four strains of seasonal influenza annually The committee reviewed randomized studies and real-world data spanning multiple seasons and numerous flu-related outcomes in support of FLUAD QUADRIVALENT to inform their recommendation SUMMIT, N.J. , June 22, 2022 /PRNewswire/ -- Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX:CSL), today announced that the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) has included FLUAD® QUADRIVALENT as a preferentially recommended seasonal influenza vaccine for adults 65 years of age and older.

CDC Advisory Committee Includes FLUAD® QUADRIVALENT as a Preferentially Recommended Influenza Vaccine for Adults 65 and Older

SUMMIT, N.J. , June 6, 2022 /PRNewswire/ -- Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX:CSL), today announced the completion of an expansion to the company's manufacturing facility in Holly Springs, N.C.

Seqirus Completes $156 Million Expansion to Holly Springs Manufacturing Facility, Optimizing Global Manufacturing Capabilities for Seasonal and Pandemic Influenza Vaccines

Seqirus is officially recognized by the U.S. government as having successfully established domestic manufacturing capability for innovative cell-based seasonal and pandemic influenza vaccines. Holly Springs, N.C.

Seqirus' Holly Springs Manufacturing Facility Designated by U.S. Government as Pandemic Ready

ST. GALLEN, Switzerland--(BUSINESS WIRE)--Regulatory News: CSL Limited (ASX: CSL; USOTC:CSLLY) yesterday announced an update regarding the Vifor Pharma AG acquisition. CSL has previously advised that it expected to be in a position to close the acquisition of Vifor Pharma AG by June 2022. While some antitrust authorities have approved the transaction, some approvals are still outstanding. Delays in the regulatory approval process are not unusual. CSL and Vifor Pharma are continuing to work clos

News for CSL Ltd Stock (CSLLY)